Abstract
Erlotinib is a standard second-line therapy for patients with advanced non-small-cell lung cancer (NSCLC). However, its efficacy for those patients with epidermal growth factor receptor (EGFR) wild-type (WT) tumors is undecided. In this randomized phase II study, NSCLC patients with EGFR-WT tumors, who had been treated with platinum-based chemotherapy but still developed disease progression, were assigned to receive second-line treatment of erlotinib plus nab-paclitaxel or erlotinib alone. We found PFS and OS were significantly improved by erlotinib plus nab-paclitaxel. The adverse events were also well tolerable.
Keywords:
EGFR; Erlotinib; NSCLC; Nab-paclitaxel.
Publication types
-
Clinical Trial, Phase II
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Albumins / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Asian People
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Disease-Free Survival
-
Erlotinib Hydrochloride
-
Female
-
Genes, erbB-1
-
Humans
-
Kaplan-Meier Estimate
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / mortality
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy
-
Paclitaxel / administration & dosage
-
Quinazolines / administration & dosage
Substances
-
130-nm albumin-bound paclitaxel
-
Albumins
-
Quinazolines
-
Erlotinib Hydrochloride
-
Paclitaxel